Inactive Instrument

Patriot Scientific Corporation Stock OTC Bulletin Board

US70336N1072

End-of-day quote OTC Bulletin Board
- ^USD	-

26/08/20	Patriot Scientific Corporation Announces Executive and Board Changes	CI
26/08/20	Patriot Scientific Corporation Announces Executive Changes	CI

Latest news : Patriot Scientific Corporation

26/08/20	Patriot Scientific Corporation Announces Executive and Board Changes	CI
26/08/20	Patriot Scientific Corporation Announces Executive Changes	CI
26/08/20	Patriot Scientific Corporation Announces Executive Changes	CI
25/08/20	Patriot Scientific Corporation Reports Earnings Results for the Full Year Ended May 31, 2020	CI
24/08/20	Mosaic ImmunoEngineering Inc acquired Patriot Scientific Corporation for $30.3 million in a reverse merger transaction.	CI
21/08/20	Patriot Scientific Corporation's Equity Buyback announced on April 24, 2006, has expired.	CI
09/04/20	Patriot Scientific Corporation Reports Earnings Results for the Third Quarter Ended February 29, 2020	CI
09/04/20	Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	CI
15/01/20	Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	CI
15/01/20	Patriot Scientific Corporation Reports Earnings Results for the Second Quarter Ended November 30, 2019	CI
12/10/19	Patriot Scientific Corporation Reports Earnings Results for the First Quarter Ended August 31, 2019	CI
12/10/19	Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	CI
05/10/19	Patriot Scientific Corporation Announces Executive Changes	CI

More news

Press Releases: Patriot Scientific Corporation

20/11/20	PATRIOT SCIENTIFIC : Change in Directors or Principal Officers (form 8-K/A)	AQ
16/10/20	PATRIOT SCIENTIFIC : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
15/10/20	PATRIOT SCIENTIFIC : Financial Statements and Exhibits (form 8-K/A)	AQ
26/08/20	PATRIOT SCIENTIFIC CORP : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
25/08/20	PATRIOT SCIENTIFIC : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ

More press releases

Mosaic ImmunoEngineering Inc. is a pre-clinical development stage biotechnology company focused on the development and commercialization of its technology to activate the innate immune system to treat and prevent cancer and infectious diseases. The company's lead product candidate, MIE-101, is based on a naturally occurring plant virus that is non-infectious in animals and humans, but activates multiple Toll-like receptors (TLRs) through its natural immune recognition. MIE-101 naturally activates the body's innate immune system when injected into a tumor, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack the injected tumor as well as other tumors in the body.

Employees

Sector

More about the company